Subscribe To
Cellectis: end of 2023 data readouts to boost car-t prospects
Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin...
November 3, 2023, 6:57 pm
Tourmaline bio announces closing of merger with talaris therapeutics and concurrent private placement of $75 million
Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovasc...
October 19, 2023, 9:37 pm
Sage therapeutics: several neuropsychiatric disorder data readouts in 2024
Sage Therapeutics, Inc. received FDA approval along with Biogen for its drug ZURZUVAE for the treatment of postpartum depression, with a planned launc...
October 18, 2023, 6:52 pm
Relmada and rel-1017: intriguing underlying efficacy in mdd ahead of eventful 2024
Phase 3 trial failures were due to abnormally high placebo responses driven by poor trial design, enrollment, and oversight. REL-1017's underlying eff...
October 13, 2023, 7:50 pm
Novartis: better margin visibility ex-sandoz
Ex-Sandoz, Novartis confirmed its yearly guidance and capital allocation priority (DPS growth and buyback). We believe NVS might experience a margin u...
October 6, 2023, 12:48 am
Roche: positive readouts from pipeline
Roche has optionality to grow its pipeline with selective M&A and new partnerships. Read more to see a detailed analysis on RHHBF stock. Read Full Sto...
September 20, 2023, 5:29 pm
Atossa therapeutics' upcoming breast cancer trial results expected to drive stock higher
Analysts at Cantor Fitzgerald have initiated coverage on Atossa Therapeutics Inc (NASDAQ:ATOS) with an ‘Overweight' rating and a $5 price target on...
September 8, 2023, 11:51 am
Relmada therapeutics: run up likely into phase 3 results, enhanced by possible interim readout
Relmada Therapeutics has provided updates on its phase 3 program of esmethadone (REL-1017) as an adjunct in major depressive disorder. An interim anal...
September 1, 2023, 6:53 pm
Adverum: h2 2023 data readouts for wet-amd gene therapy
14-week data from the phase 2 LUNA study, using Ixo-vec for the treatment of patients with wet age-related macular degeneration, expected in late Q3 o...
August 23, 2023, 2:46 pm
Replimune: q4 2023 data readouts of rp1 makes this a must watch
Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous s...
August 14, 2023, 5:28 pm
Xenon is well-funded heading into key readouts
Xenon Pharmaceuticals has a strong cash position of $652.2M and an estimated cash runway of approximately 3.11 years. The company's financial health i...
August 13, 2023, 9:20 am
Bicycle therapeutics: decent upside opportunity, mid-stage data readouts due
Bicycle Therapeutics is an intriguing play in the drug development space. Using its fully synthetic short peptides, the company has developed two mid-...
July 31, 2023, 7:07 pm
Checkpoint therapeutics: cosibelimab data bolsters case for dual-approval in cscc
Checkpoint Therapeutics announced updated, longer-term data for cosibelimab from their pivotal trial in locally advanced and metastatic cutaneous squa...
July 30, 2023, 4:19 am
Tesla created secret team to suppress thousands of driving range complaints
About a decade ago, Tesla rigged the dashboard readouts in its electric cars to provide “rosy” proj...
July 27, 2023, 6:08 am
Terns pharmaceuticals: upcoming obesity data is one of many catalysts coming up
Terns Pharmaceuticals has a promising pipeline with potential best-in-class therapies for obesity and NASH. Upcoming data ...
June 1, 2023, 6:47 pm
Gilead: pharma play worth watching on multitude of asco data readouts
Gilead Sciences, Inc. is expected to offer 30 Abstract Presentations at the ASCO 2023 medical meeting to be held between June 2 - 6 of 2023. Product s...
May 31, 2023, 7:11 pm
Roivant sciences: coming nicely to the boil with multiple opportunities
Roivant Sciences recently won approval for a topical cream, VTAMA, that looks set to achieve blockbuster (>$1bn per annum) sales. The company has seve...
May 26, 2023, 10:25 pm
Mindmed a ‘speculative buy' ahead of key trial data readouts, broker says
Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their ‘Speculative Buy' rating for MindMed (NASDAQ:MNMD, NEO:MMED) after the clinical...
May 9, 2023, 11:13 am
Why bioxcel therapeutics stock marched higher today
BioXcel Therapeutics announced 2023 first-quarter earnings today. While revenue for the three-month period wasn't a needle-mover, investors appear to ...
May 8, 2023, 4:54 pm
Pyxis oncology: cashed up and entering the clinic
PYXS has initiated dosing with PYX-201 in a phase 1 study, with preliminary results due in early 2024. PYXS expects to initiate dosing in a phase 1 st...
March 27, 2023, 7:32 am